Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Dec 20;7(14):1948-60.
doi: 10.1016/j.intimp.2007.07.017. Epub 2007 Aug 9.

Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers

Sunil Kurian  1 , Yevgeniy Grigoryev, Steve Head, Daniel Campbell, Tony Mondala, Daniel R Salomon
Affiliations
Review

Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers

Sunil Kurian et al. Int Immunopharmacol. .

Abstract

The field of biomarker discovery made a significant leap over the past few decades. As we enter the Era of the Human Genome, thousands of biomarkers can be identified in a relatively high-throughput fashion. While such magnitude and diversity of biomarkers can be seen as a challenge by itself, the field is being moved forward by new advances in bioinformatics and Systems Biology. Because of the life and death nature of end stage organ failure that transplantation treats, the severe donor organ shortage, and the powerful and toxic drug therapies required for the lifetimes of transplant patients, we envision a future for biomarkers as tools to diagnose disease in its early stages, predict prognosis, suggest treatment options and then assist in the implementation of therapies. By harnessing the power of multiple technologies in parallel makes it possible to discover and then validate the next generation of biomarkers for transplantation. We see the road ahead diverge into two paths: one from biomarkers to diagnosis and therapy and the other to a new level of insight into the complex molecular networks that determine when a healthy state becomes diseased and dysfunctional.

PubMed Disclaimer

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. BDW Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95. - PubMed
    1. Gold P, Freedman SO. Demonstration Of Tumor-Specific Antigens In Human Colonic Carcinomata By Immunological Tolerance And Absorption Techniques. J Exp Med. 1965;121:439–62. - PMC - PubMed
    1. Allhoff EP, Proppe KH, Chapman CM, Lin CW, Prout GR., Jr Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol. 1983;129(2):315–8. - PubMed
    1. Kuriyama M, Wang MC, Lee CI, Papsidero LD, Killian CS, Inaji H, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res. 1981;41(10):3874–6. - PubMed
    1. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol. 2002;29(3):231–45. - PubMed

MeSH terms